| Pulmonary arterial hypertension

Revatio vs Tadliq

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.

Deep comparison between: Revatio vs Tadliq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTadliq has a higher rate of injection site reactions vs Revatio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tadliq but not Revatio, including UnitedHealthcare

Category

Revatio

Tadliq

At A Glance

RouteOral or IV bolus

FrequencyThree times a day

ClassPDE-5 inhibitor

RouteOral

FrequencyOnce daily

ClassPDE5 inhibitor

Indications

Pulmonary arterial hypertension

Pulmonary arterial hypertension

Dosing

Pulmonary arterial hypertension Adults: 20 mg orally three times a day (may titrate to 80 mg three times a day) or 10 mg IV bolus three times a day; pediatric patients <=20 kg: 10 mg orally three times a day; 20-45 kg: 20 mg three times a day; >45 kg: 20 mg three times a day (may titrate to 40 mg three times a day).

Pulmonary arterial hypertension 40 mg (10 mL) once daily with or without food; start at 20 mg (5 mL) once daily in mild-to-moderate renal or mild-to-moderate hepatic impairment, increasing to 40 mg based on tolerability; avoid in severe renal impairment and severe hepatic impairment; when initiating TADLIQ in patients on ritonavir for at least one week, start at 20 mg once daily and increase to 40 mg based on tolerability; when starting ritonavir in patients already on TADLIQ, stop TADLIQ at least 24 hours prior and resume at 20 mg once daily after at least one week.

Contraindications

Concomitant use of organic nitrates in any form, either regularly or intermittently, due to risk of hypotension
Concomitant use of riociguat, a guanylate cyclase stimulator
Known hypersensitivity to sildenafil or any component of the tablet, injection, or oral suspension

Concomitant use of any form of organic nitrate, either regularly or intermittently
Concomitant use of guanylate cyclase (GC) stimulators such as riociguat
Known serious hypersensitivity to tadalafil (TADLIQ, ADCIRCA, or CIALIS)

Drug Interactions

1152View drug interactions

1154View drug interactions

Adverse Reactions

Most common (>=10%) Headache, flushing, pain in limb, myalgia, back pain, dyspepsia, diarrhea

Serious Hypotension, vision loss, hearing loss, priapism, vaso-occlusive crisis

Postmarketing Myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, pulmonary hemorrhage, seizure, NAION

Most common (>=9%) Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, pain in extremity, nausea, back pain, dyspepsia, nasal congestion

Serious Hypotension, visual loss, hearing loss, priapism

Postmarketing Serious cardiovascular events (myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, tachycardia), hypersensitivity reactions (urticaria, Stevens-Johnson syndrome, exfoliative dermatitis), migraine, seizure, transient global amnesia, visual field defect, retinal vein occlusion, retinal artery occlusion, NAION, sudden hearing decrease or loss, priapism

Pharmacology

Sildenafil is a selective inhibitor of cGMP-specific PDE-5 in pulmonary vascular smooth muscle; by blocking PDE-5-mediated cGMP degradation, it elevates cGMP levels resulting in relaxation and vasodilation of the pulmonary vascular bed in patients with PAH.

PDE5 inhibitor; tadalafil selectively inhibits phosphodiesterase type 5, increasing cGMP concentrations in pulmonary vascular smooth muscle, resulting in relaxation and vasodilation of the pulmonary vascular bed in patients with pulmonary arterial hypertension.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Revatio